No abstract available
Keywords:
Cancer immunotherapy; Checkpoint inhibitor toxicity; Immune-mediated arthritis; Immune-related adverse event; mCRPC.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Edema / chemically induced*
-
Edema / drug therapy
-
Humans
-
Male
-
Neoplasm Metastasis
-
Phthalazines / administration & dosage
-
Phthalazines / adverse effects
-
Piperazines / administration & dosage
-
Piperazines / adverse effects
-
Prostatic Neoplasms, Castration-Resistant / drug therapy
-
Synovitis / chemically induced*
-
Synovitis / drug therapy
-
Treatment Outcome
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Phthalazines
-
Piperazines
-
durvalumab
-
olaparib